Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Tarsus Pharmaceuticals Inc shares valued at $912,961 were sold by LINK WILLIAM J PHD on Aug 12 ’24. At $26.08 per share, LINK WILLIAM J PHD sold 35,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, FLYING L PARTNERS XI LLC purchased 35,000 shares, netting a total of over 939,750 in proceeds.
Before that, Farrow Jeffrey S had sold 10,445 shares from its account. In a trade valued at $286,924, the insider traded Tarsus Pharmaceuticals Inc shares for $27.47 each. Upon closing the transaction, the insider’s holdings decreased to 10,445 shares, worth approximately $0.89 million.
As published in their initiating research note from Goldman on November 20, 2023, Tarsus Pharmaceuticals Inc [TARS] has been a Neutral and the price target has been revised to $19. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid July. As of May 18, 2023, Guggenheim has initiated its “Buy” rating for TARS. Earlier on August 01, 2022, Barclays initiated its rating. Their recommendation was “an Overweight” for TARS stock.
Analyzing TARS Stock Performance
During the last five days, there has been a surge of approximately 5.50%. Over the course of the year, Tarsus Pharmaceuticals Inc shares have dropped approximately -11.29%. Shares of the company reached a 52-week high of $57.14 on 01/02/25 and a 52-week low of $43.61 on 01/14/25. A 50-day SMA is recorded $50.51, while a 200-day SMA reached $36.76. Nevertheless, trading volume fell to 0.57 million shares from 0.46 million shares the previous day.
Support And Resistance Levels for Tarsus Pharmaceuticals Inc (TARS)
According to the 24-hour chart, there is a support level at 47.77, which, if violated, would cause prices to drop to 46.43. In the upper region, resistance lies at 50.24. The next price resistance is at 51.36. RSI (Relative Strength Index) is 46.44 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.39, which suggests the price will decrease in the coming days. Percent R is at 59.28%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Tarsus Pharmaceuticals Inc (TARS)?
On December 21, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $40.
